An Investigator initiated, open-label, Single arm, non-randomized clinical study to evaluate the effectiveness, tolerability and safety of Besifloxacin hydrochloride in the treatment of subjects suffering from Gram-negative facial folliculitis. - Gram Negative Folliculitis (GNF)

Start Date03 May 2019

Sponsor / Collaborator-

CTRI/2018/07/014840

/ Not yet recruitingPhase 4IIT

A Randomized Controlled Trial to assess the efficacy of Topical Besifloxacin0.6% versus Moxifloxacin0.5% in Bacterial Conjunctivitis.

Start Date17 Jul 2018

Sponsor / Collaborator-

NCT04542759

/ CompletedPhase 1IIT

Effect of Topical Besifloxacin on Ocular Surface Bacterial Microbiota Prior to Cataract Surgery

Describe the efficacy of the use of topical besifloxacin in reducing the conjunctival microbiota as a prophylactic measure in patients scheduled for cataract surgery.

Start Date01 Jan 2017

Sponsor / Collaborator-

100 Clinical Results associated with Besifloxacin Hydrochloride

100 Translational Medicine associated with Besifloxacin Hydrochloride

100 Patents (Medical) associated with Besifloxacin Hydrochloride

176

Literatures (Medical) associated with Besifloxacin Hydrochloride

01 Dec 2025·JOURNAL OF BIOLOGICAL PHYSICS

Structural insight in understanding the impact of mutation at position 88 and 94 of DNA gyrase A of Mycobacterium tuberculosis in developing resistance against delafloxacin

Article

Author: Singh, Satendra ; Rai, Sumit Kumar ; Singh, Dev Bukhsh

DNA gyrase is a target for treating tuberculosis caused by Mycobacterium tuberculosis. Many cases of antibiotic resistance have been reported due to different point mutations in the Chain A of DNA gyrase. Based on literature information on drug-resistance related study for DNA gyrase, we generated 4 different mutant models 3ILW_G88A, 3ILW_G88C, 3ILW_D94G, and 3ILW_D94H by inserting two mutations at each position 88 and 94 in DNA gyrase chain A. Antibiotics Clinafloxacin, Gatifloxacin, Moxifloxacin, Sitafloxacin, Prulifloxacin, Besifloxacin, Delafloxacin, Ozenoxacin were docked with 3ILW_wild to understand their stability, binding affinity, and interaction pattern with the wild-type DNA gyrase (3ILW_wild). Delafloxacin has shown more stable and favorable binding interaction with the 3ILW_wild (BFE, -8.6 kcal/mol). Docking of Delafloxacin with four mutant models (3ILW_G88A, 3ILW_G88C, 3ILW_D94G, and 3ILW_D94H) was performed to understand the impact of these mutations on binding stability and interaction. A complete loss of binding interaction with Ser118 and Pro119 was observed in mutant complexes as compared to 3ILW_wild, suggesting the role of these residues in developing resistance. Molecular dynamics simulations over 100 ns were carried out for the complex of Delafloxacin with 3ILW_wild and four mutant models. Parameters like RMSD, RMSF, radius of gyration, H-bond, and solvent-accessible surface area revealed that the mutant models are more rigid and less flexible as compared to wild-type DNA gyrase, which in turn results in loss of some interactions. It is worth noting that mutation at position 94 of DNA gyrase A has a very profound effect as it shows a positive contribution towards increased resistance due to reduced binding affinity with delafloxacin. This study explains the structural changes and mechanism behind the resistance against Delafloxacin, and may also guide the structural changes required in existing Delafloxacin or other antibiotics to develop new therapeutics to overcome the issue of resistance.

20 Oct 2025·ACS Applied Bio Materials

Hyaluronic Acid Microgels as Sequential Drug Delivery Systems

Article

Author: Maier, Michael Alexander ; Pieper, Maria Isabell ; Pich, Andrij

Precise delivery of drugs is essential for improving medical treatment outcomes and minimizing side effects. While there have been advancements in preparing drug delivery systems that release their payload in response to specific stimuli, challenges remain in creating carriers, capable of taking up multiple substances and releasing them in sequence. However, this approach could facilitate synergistic effects and reduce the dosing frequency. In this work, we synthesized hyaluronic acid microgels and investigated their suitability for sequential release of multiple compounds. We modified hyaluronic acid with methacrylate groups (6/15/30/60 mol % of HA repeating units), which allow for cross-linking. These precursors were dissolved in water at a concentration of 50 mg mL^-1, and microgels within a size range of 114-250 μm were formed via droplet-based microfluidics. After detailed characterization of the polyanionic microgels, we examined the loading of three cationic (model) drugs: doxorubicin, methylene blue, and besifloxacin. Release was investigated under varying conditions (pH and ionic strength), revealing a rapid burst release within a few hours in a physiological environment. We then examined the loading of larger, fluorescently labeled biomolecules, which remained trapped within the polymeric network under similar conditions. Sustained release over several days was achieved through enzymatic degradation of the microgels using hyaluronidase. Afterward, we loaded both types of payload, drug and biomolecule, into the microgels and released them in sequence. We show that release profiles can be controlled by varying enzyme concentration or the microgels' cross-linking density. Our approach facilitates the sequential delivery of two substances and paves the way toward more effective treatment strategies.

01 Jun 2025·Chemical Biology & Drug Design

Identification and Evaluation of Besifloxacin as Repurposed Antifungal Drug in Combination With Fluconazole Against Candida albicans

Article

Author: Pawaskar, Ameya ; Idicula‐Thomas, Susan ; Metkari, Siddhanath ; Chakraborty, Shuvechha ; Madan, Taruna

ABSTRACT:

Emergence of life‐threatening fungal infections like systemic candidiasis concurrently with bacterial infections and limitations of current antifungal therapies warrant the discovery of novel inhibitors. We identified besifloxacin (BS), an FDA‐approved antibacterial, as a potent antifungal inhibitor. A combination of besifloxacin with fluconazole showed a positive synergy (δ = 29.58) resulting in 80% inhibition of microbial growth. BS was able to reduce the MIC of FLC from 2 mg/L to 0.5 mg/L when used in combination. Additionally, in murine systemic Candida infection, BS reduced fungal load by 83% in mice kidneys at a dose of 100 mg/kg/day. The findings demonstrated the antifungal potential of BS, proposing its use in combination therapy with fluconazole to combat resistance through alternative mechanisms.

News (Medical) associated with Besifloxacin Hydrochloride

01 Feb 2024

·www.biospace.com

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1st Experienced executives bring extensive track record in products for retinal and ophthalmology diseases MELBOURNE, Australia, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Julie Clark, MD, MS, as Senior Vice President (SVP), Clinical Development, and Fang Li, Ph.D. RAC, as SVP, Regulatory Affairs, effective February 1, 2024. Dr. Clark and Dr. Li will report to Opthea Chief Executive Officer, Frederic Guerard, PharmD, MS, and will join the Opthea Executive Management Team. “It is my great pleasure to welcome two ophthalmology experts, Dr. Clark and Dr. Li, to the Company as we prepare for the next stage in our growth and work towards advancing the development of sozinibercept (OPT-302),” said Dr. Guerard. “Their past contributions to the development and registration of ophthalmology therapies such as IZERVAY™, BEOVU®, and EYLEA®, will be instrumental to the potential success of our lead program investigating sozinibercept, currently in two Phase 3 pivotal trials.” Dr. Clark shared, “I am thrilled to join Opthea as we prepare to complete patient enrollment in the pivotal Phase 3 clinical program for sozinibercept in the first half of 2024. The majority of my career has been dedicated to the clinical development of novel therapies for retinal diseases. Sozinibercept could be the first new drug for wet age-related macular degeneration (AMD) in more than 15 years, with the potential to deliver superior visual gains when administered in combination with standard of care therapy. I look forward to contributing to bringing this novel product candidate to patients with serious retinal disease.” Dr. Li commented, “As we work towards the potential release of topline results for our Phase 3 program in mid-2025, I am excited to apply my expertise to support the development and execution of our regulatory strategy and potential filings for sozinibercept in the U.S. and other markets. I look forward to the opportunity to bring Opthea’s innovative potential medicine through the regulatory process for the benefit of patients with retinal diseases.” Julie Clark, MD, MS With more than 15 years of experience in ophthalmology medical and clinical development, Dr. Clark brings expertise in both early and late-stage programs, regulatory submissions, and approvals. Her contributions include substantial support for the approval and launches of retinal therapies such as EYLEA®, JETREA® and BEOVU®. In Dr. Clark’s most recent position as Vice President Clinical Development at IVERIC bio, Inc., An Astellas Company, she oversaw the development program leading to the August 2023 U.S. Food and Drug Administration (FDA) approval of IZERVAY™, a complement inhibitor approved for the treatment of geographic atrophy secondary to age-related macular degeneration. Dr. Clark previously served as Chief Medical Officer at Adverum Biotechnologies Inc, where she played a crucial role in developing intravitreal delivered gene therapy for retinal diseases. Dr. Clark is a graduate of Wake Forest University and Wake Forest University School of Medicine in Winston-Salem, NC, U.S. Fang Li, PhD, RAC Dr. Li brings over 30 years of expertise in drug development and more than 20 years in regulatory affairs experience. Her experience spans various domains including small molecules, biologics, gene therapy, over-the-counter products, in-vitro diagnostic products and medical devices, with a specific focus on ophthalmology. She has held key roles at prominent ophthalmology companies such as Novartis AG, Alcon Inc., and Bausch + Lomb Corporation. Dr. Li's extensive background includes significant involvement in health authority interactions, U.S. FDA advisory committee meeting preparation and the establishment and leadership of regulatory teams. She has a proven track record of success in obtaining product approvals in the U.S. and other regions. Throughout her career, Dr. Li has played a pivotal role in leading numerous FDA drug approvals, specifically contributing to the approval of ophthalmology products like JETREA®, LOTEMAX® Ointment, SYSTANE® COMPLETE. She has also contributed to the development and registration of other ophthalmology drug products such as BEOVU®, PAZEO®, LOTEMAX® GEL, BESIVANCE®, and VYZULTA®. Fang holds a PhD in Medicinal Chemistry from China Pharmaceutical University, China. About Opthea Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including neovascular (wet) age-related macular degeneration (wet AMD). Opthea’s lead product candidate sozinibercept is being evaluated in two pivotal Phase 3 clinical trials (ShORe, NCT04757610, and COAST, NCT04757636) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care. To learn more, visit and follow us on X and LinkedIn. Inherent risks of Investment in Biotechnology Companies There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments. Forward-looking Statements This ASX announcement contains certain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. The words “expect”, “believe,” “should”, “could”, “may”, “will”, “plan” and other similar expressions are intended to identify forward-looking statements. Forward-looking statements in this ASX announcement include statements regarding expectations on the outcomes of Opthea’s Phase 3 clinical trials of sozinibercept, the potential for sozinibercept as a combination therapy to be the first therapy to achieve superior visual outcomes over anti-VEGF-A monotherapy and improve vision outcomes for patients with wet AMD, the expected timing for completion of enrollment for the Phase 3 studies and topline data, the market opportunity for sozinibercept, and the future performance of Opthea. Forward-looking statements, opinions and estimates provided in this ASX announcement are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current conditions. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. They involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Opthea and its directors and management and may involve significant elements of subjective judgment and assumptions as to future events that may or may not be correct. These statements may be affected by a range of variables which could cause actual results or trends to differ materially, including but not limited to future capital requirements, the development, testing, production, marketing and sale of drug treatments, regulatory risk and potential loss of regulatory approvals, ongoing clinical studies to demonstrate sozinibercept safety, tolerability and therapeutic efficacy, additional analysis of data from Opthea’s Phase 3 clinical trials, timing of completion of Phase 3 clinical trial patient enrollment and clinical research organization and labor costs, intellectual property protections, and other factors that are of a general nature which may affect the future operating and financial performance of the Company including risk factors set forth in Opthea’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on September 28, 2023 and other future filings with the SEC. Actual results, performance or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Subject to any continuing obligations under applicable law or any relevant ASX listing rules, Opthea disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this ASX announcement to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based, except as otherwise required by applicable law. Authorized for release to ASX by Frederic Guerard, CEO Company & Media Enquiries: Rudi Michelson Monsoon Communications Tel: +61 (0) 3 9620 3333 Investor Enquiries PJ Kelleher LifeSci Advisors Email: pkelleher@lifesciadvisors.com Join our email database to receive program updates: Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web:

Phase 3Executive ChangeDrug Approval

26 Apr 2023

·www.biospace.com

Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs

Oculis establishes its US headquarters in Boston, MA, a world-renowned biotech hub, to support its continued expansion following OCS listing into NASDAQ Oculis’s finance and development team strengthened by US-based hires, including Dr. Fang Li as Senior Vice President, Regulatory Affairs, who successfully led important FDA new drug approvals in ophthalmology US-based office established ahead of important near-term clinical and late-stage data milestones such as results from Stage 1 of Phase 3 DIAMOND study of OCS-01 in DME and from Phase 3 OPTIMIZE study of OCS-01 in Inflammation and Pain following cataract surgery later in 2023 ZUG, Switzerland, and BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the opening of its Boston, Massachusetts office, expanding its US presence in preparation of becoming an active player in the US market and demonstrating execution of its strategy. Located in the heart of the largest national and global life sciences hub, the new Boston office will serve as a strategic location for Oculis to support its US operations in anticipation of important near-term clinical and late-stage data milestones such as results from Stage 1 of the Company’s Phase 3 DIAMOND study of OCS-01 in DME and the Phase 3 OPTIMIZE study of OCS-01 in Inflammation and Pain following cataract surgery later this year. The expansion of Oculis’s presence in the US accompanies the recent strengthening of its finance and development team. This includes the hiring of Dr. Fang Li as the new US-based Senior Vice President, Regulatory Affairs. Dr. Li brings to Oculis over 25 years of drug development experience, having worked in regulatory affairs for over 20 years with leading ophthalmology companies such as Novartis, Alcon and Bausch & Lomb, among others. She has extensive experience with health authority interactions, FDA advisory committee meeting preparation, and building and leading regulatory teams. She has a proven success record in gaining product approvals in the US and other regions. Throughout her career, she successfully led numerous FDA drug approvals in ophthalmology including for Jetrea, Lotemax Ointment, Systane Complete and worked on several other ophthalmology drug products such as Beovu, Lotemax Gel, Besivance, and Vyzulta. Riad Sherif, MD, CEO of Oculis, said, “Together with the strengthening of our global development team by hiring Dr Fang Li, the opening of our US headquarters is a major milestone for Oculis and represents an exciting new chapter for our team. Boston is a city with a long history of innovation and world-renowned medical center and we are excited to work with the rich pool of talent and partners available in the area, and to take part in the local biotech ecosystem.” About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculis’s highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop retinal candidate for diabetic macular edema (DME); OCS-02, a topical eye drop biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’s goal is to deliver life-changing treatments to patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors. For more information, please visit: Contacts Investor Relations Riad Sherif MD, CEO riad.sherif@oculis.com Ms Sylvia Cheung, CFO sylvia.cheung@oculis.com Media Relations Consilium Strategic Communications Amber Fennell, Tracy Cheung, David Daley oculis@consilium-comms.com Cautionary Statement Regarding Forward Looking Statements This press release contains forward looking statements and information. For example, statements regarding expected future milestones and catalysts; the initiation, timing, progress and results of Oculis’ clinical and preclinical studies; Oculis’ research and development programs, regulatory and business strategy, future development plans, and management; Oculis’ ability to advance product candidates into, and successfully complete, clinical trials; and the timing or likelihood of regulatory filings and approvals, are forward looking. All forward looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ proxy statement and the prospectus for Oculis’ offering, and any other documents filed with the U.S. Securities and Exchange Commission (the “SEC”). Copies of these documents are available on the SEC’s website, Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Executive ChangePhase 3

100 Deals associated with Besifloxacin Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D08872	Besifloxacin Hydrochloride	S01AE08	DB06771

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Conjunctivitis, Bacterial	United States	Bausch & Lomb, Inc.	28 May 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
acute bacterial conjunctivitis	Phase 3	-	Bausch & Lomb, Inc.	01 Jun 2006
Corneal Ulcer	Phase 2	United States	Bausch & Lomb, Inc.	01 Jul 2013
Lacrimal Duct Obstruction	Phase 1	United States	Bausch & Lomb, Inc.	01 Sep 2011
Cataract	Phase 1	United States	Bausch & Lomb, Inc.	01 Feb 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01296542 (CTgov)	Phase 4	Cataract	60	Moxifloxacin Ophthalmic (VIGAMOX)	zupkdayhkc = aiakefgeqg fxjvxjyrvj (xedntyylcq, ihksckrjoz - uyyvihyezn) View more	-	08 Dec 2020
				Besifloxacin Ophthalmic (Besivance)	zupkdayhkc = wrrkylxews fxjvxjyrvj (xedntyylcq, gbaqaxhvww - jiuzdowelo) View more
NCT00348348 \| NCT00622908 \| NCT00347932 (Pubmed \| PLoS One)	Phase 2	Conjunctivitis, Bacterial	1,041	Besifloxacin ophthalmic suspension 0.6%	quhzwaogjy(srukvqatok) = hfbdmpvbxy tchkxqbpmp (ucfrxjrisn )	-	01 Jan 2020
				Vehicle	quhzwaogjy(srukvqatok) = xvaafjmybi tchkxqbpmp (ucfrxjrisn )
NCT01296191 (CTgov)	Phase 4	Cataract	120	Moxifloxacin (VIGAMOX)	grkvcenuvg(lxsmthsxnl) = oxciohhgkv ciqyekhjwo (xvopsehcvg, 232.285) View more	-	29 Oct 2019
				besifloxacin (Besivance)	grkvcenuvg(lxsmthsxnl) = ikrobhonuz ciqyekhjwo (xvopsehcvg, 39.6325) View more
NCT01431170 (CTgov)	Phase 1	Lacrimal Duct Obstruction	24	Besivance Treatment Group (Besivance Treatment Group)	cmoolebxwn = zfuqfctllh lsqyyenitq (xjzsfllyhm, bathndshya - kckbafftah) View more	-	09 Jun 2016
				Polytrim Treatment Group (Polytrim Treatment Group)	cmoolebxwn = apbtqiyrpg lsqyyenitq (xjzsfllyhm, fjlejbxsyf - kooxtioudy) View more
NCT01928693 (Eye02, CTgov)	Phase 2	Corneal Ulcer	2	Besivance 0.6% Ophthalmic Suspension (Besivance 0.6% Ophthalmic Suspension)	xhcgwhmyiq(uaqqbuyubb) = lakcmnbkvm oowrnezpez (bkicvqfsvk, qubguybuyu - yyoybqwflw) View more	-	13 Aug 2015
				Zymaxid 0.5% Ophthalmic Solution (Zymaxid 0.5% Ophthalmic Solution)	obpcqjboks = ddmnjatwnq trwtlkhguw (grecpfyudz, ihyfamzqqy - onpoyjbgpl) View more
ARVO2015	Not Applicable	Lacrimal Duct Obstruction	-	Besivance	ptqapofdyd(dandavmwah) = hdobzyilwn ooiydmedqn (nlorbberbt ) View more	-	01 Jun 2015
				Polytrim	ptqapofdyd(dandavmwah) = xghqoyoyxg ooiydmedqn (nlorbberbt ) View more
NCT01740388 (CTgov)	Phase 3	acute bacterial conjunctivitis \| Conjunctivitis, Bacterial	136	Besifloxacin (Besifloxacin)	nxpcznghvg = xmpaaqwkvi xjuyplhxbn (utsgvlrwkb, xkgeethust - qbzngpgdec) View more	-	17 Sep 2014
				Vehicle (Vehicle)	nxpcznghvg = qimdvarouw xjuyplhxbn (utsgvlrwkb, rgcrxtfcpb - zfqmmvtvht) View more
NCT01330355 (CTgov)	Phase 3	acute bacterial conjunctivitis \| Conjunctivitis, Bacterial	33	Besivance (Besivance)	iyqcmxaovs = vlfanstesa nmebngtfpj (szbtjlodjm, diyndqacjr - ruuvzzcsht) View more	-	03 Sep 2014
				Gatifloxacin (Gatifloxacin)	iyqcmxaovs = aaudwogwjd nmebngtfpj (szbtjlodjm, ibswpocwzp - gsljpfpbqr) View more
NCT01478256 (CTgov)	Phase 4	Blepharitis	30	Besifloxocin (Besifloxocin)	vbfxhnnirt = mlzqdbvyfs bedawjswth (jpidejygvp, tpnwifiwld - ourwvsollg) View more	-	20 Nov 2013
				Erythromycin (Erythromycin)	vbfxhnnirt = spxudjsufg bedawjswth (jpidejygvp, ckphvaegcd - jxcdfgyesl) View more
NCT01175590 (CTgov)	Phase 3	Conjunctivitis, Bacterial	518	Besivance (Besivance)	eykcjgxodg = mjnnrnhixc gmjcjdyctc (lgzgdefsrs, yijwdqlffe - ubetvxxmhg) View more	-	01 May 2013
				Vehicle (Vehicle)	eykcjgxodg = erxicrxczq gmjcjdyctc (lgzgdefsrs, hlsjkfvwkb - yfoayhldhf) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Besifloxacin Hydrochloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation